Status:
TERMINATED
Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus
Lead Sponsor:
NYU Langone Health
Conditions:
Avascular Necrosis
Eligibility:
FEMALE
18-75 years
Phase:
PHASE2
Brief Summary
This study uses the cholesterol lowering drug atorvastatin, also known as lipitor, to show reduction of avascular necrosis in steroid treated lupus patients. Avascular necrosis is a disease resulting ...
Detailed Description
If you have started on prednisone 30mg or greater and expect to be on it for greater than two weeks you may be a candidate for the study. Also, you would need to be enrolled in the study within three ...
Eligibility Criteria
Inclusion
- All individuals must fulfill 4 of the revised criteria of the American College of Rheumatology for SLE
- Patient started on corticosteroids at a dose of at least .5mg/kg for an interval greater than two weeks
- To be able to come for all follow-up visits for nine months
- No contraindications to undergoing MRI
- Age 18-75 years
Exclusion
- Evidence of liver disease, not secondary to active lupus, or liver enzyme greater than 2x normal
- Elevated CPK at baseline
- Pregnancy or Lactating
- Allergy to a statin
- Current or recent use of a statin within 3 months
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00412841
Start Date
November 1 2002
End Date
January 1 2008
Last Update
November 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The New York University Hospital For Joint Diseases
New York, New York, United States, 10003